Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Hepion Pharmaceuticals receives DSMB approval to continue AMBITION trial » 07:35
12/29/20
12/29
07:35
12/29/20
07:35
HEPA

Hepion Pharmaceuticals

$2.11 /

-0.06 (-2.76%)

Hepion Pharmaceuticals…

Hepion Pharmaceuticals announced that an independent Data Safety Monitoring Board, or DSMB, has approved the continuation of the company's Phase 2a AMBITION clinical trial. Two interim analyses were performed by a DSMB to evaluate the safety and tolerability of the 75 mg CRV431 dose cohort in NASH patients. The first analysis occurred half-way through the first dosing cohort and this, the second analysis, occurred at the completion of the first dosing cohort. Hepion's novel drug candidate, CRV431, is a pan-cyclophilin inhibitor that inhibits multiple forms of cyclophilins. Cyclophilins, of which there are 17 known isoforms in humans, play a central role in protein folding and contribute to numerous biological effects including inflammation and fibrosis. The AMBITION trial is the first placebo-controlled study of CRV431 in NASH patients with evidence of moderate-to-severe fibrosis. In this study, which is being conducted at 10 U.S. sites, CRV431 is administered orally, once-daily for 28 days. The primary objectives of the AMBITION trial are to assess safety and tolerability of CRV431, as well as to delineate pharmacokinetics. The secondary outcome measure of this Phase 2a trial is to evaluate decreases in non-invasive antifibrotic markers from baseline to the end of the study. Data from the AMBITION trial will be used alongside Hepion's proprietary AI-POWRTM to guide and enrich future study design.

ShowHide Related Items >><<
HEPA Hepion Pharmaceuticals
$2.11 /

-0.06 (-2.76%)

HEPA Hepion Pharmaceuticals
$2.11 /

-0.06 (-2.76%)

12/01/20 Roth Capital
Hepion Pharmaceuticals price target lowered to $8 from $14 at Roth Capital
07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
  • 25
    Nov
HEPA Hepion Pharmaceuticals
$2.11 /

-0.06 (-2.76%)

Over a month ago
Hot Stocks
Hepion announces FDA clearance of IND application for CRV431 for Covid » 07:38
12/22/20
12/22
07:38
12/22/20
07:38
HEPA

Hepion Pharmaceuticals

$2.11 /

+0.19 (+9.90%)

Hepion Pharmaceuticals…

Hepion Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted its investigational new drug application for CRV431, a novel cyclophilin inhibitor for the treatment of COVID-19. On July 7, Hepion announced a potential two-pronged strategy to treat COVID-19. First, preclinical cell culture experiments demonstrated CRV431 decreased SARS-CoV-1 production of infectious virus. Second, in a non-viral, acute lung injury model, CRV431 demonstrated attenuated lung inflammation and damage similar to or better than dexamethasone, including reductions in neutrophils and IL-6. This property may be beneficial to patients suffering longer term consequences of COVID-19 infection, including acute respiratory distress syndrome . Importantly, COVID-19 patients developing ARDS have a higher mortality rate.1 Taken together, this dual mode of action suggested that CRV431 may offer an opportunity to treat both the viral infection as well as lung injury in COVID-19. "The recent identification of a mutational variant of SARS-CoV-2 that is potentially more infectious than previous strains is a reminder that we must continue to battle this virus on all fronts. Host cyclophilins play a key role in the propagation of viruses. CRV431, a cyclophilin inhibitor, interrupts the ability of the virus to use these human cyclophilins and thereby reduces viral propagation. As such, CRV431 is likely less prone to treatment resistance that may be seen when viral mutations occur," stated Dr. Daren Ure, Hepion's Chief Scientific Officer. "There is a great deal of well-deserved optimism now that vaccines have been approved. However, for the foreseeable future, we anticipate there will continue to be the need for active antiviral treatments as well as treatment for ARDS. CRV431 potentially offers both."

ShowHide Related Items >><<
HEPA Hepion Pharmaceuticals
$2.11 /

+0.19 (+9.90%)

HEPA Hepion Pharmaceuticals
$2.11 /

+0.19 (+9.90%)

12/01/20 Roth Capital
Hepion Pharmaceuticals price target lowered to $8 from $14 at Roth Capital
07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
  • 25
    Nov
HEPA Hepion Pharmaceuticals
$2.11 /

+0.19 (+9.90%)

HEPA Hepion Pharmaceuticals
$2.11 /

+0.19 (+9.90%)

Options
Largest borrow rate increases among liquid names » 08:45
12/18/20
12/18
08:45
12/18/20
08:45
GP

GreenPower Motor

$17.80 /

-0.36 (-1.98%)

, FUBO

FuboTV

$35.28 /

+5.71 (+19.31%)

, TRXC

TransEnterix

$0.56 /

-0.0184 (-3.18%)

, VLDR

Velodyne Lidar

$20.60 /

+0.03 (+0.15%)

, VFF

Village Farms

$9.93 /

-0.32 (-3.12%)

, ROOT

Root

$14.12 /

+0.21 (+1.51%)

, HEPA

Hepion Pharmaceuticals

$1.90 /

+0.02 (+1.06%)

, IPOC

Social Capital Hedosophia Holdings III

$11.01 /

+0.13 (+1.19%)

, SOL

ReneSola

$7.70 /

-0.38 (-4.70%)

, LAC

Lithium Americas

$9.37 /

-0.145 (-1.52%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: GreenPower Motor Company (GP) 46.52% +9.30, fuboTV (FUBO) 17.16% +4.20, TransEnterix (TRXC) 10.44% +0.26, Velodyne Lidar (VLDR) 11.41% +0.24, Village Farms International (VFF) 14.34% +0.19, Root Inc (ROOT) 3.30% +0.18, Hepion Pharmaceuticals (HEPA) 19.68% +0.18, Social Capital Hedosophia Holdings III (IPOC) 1.09% +0.17, ReneSola (SOL) 16.48% +0.15, and Lithium Americas (LAC) 16.63% +0.14.

ShowHide Related Items >><<
VLDR Velodyne Lidar
$20.60 /

+0.03 (+0.15%)

VFF Village Farms
$9.93 /

-0.32 (-3.12%)

TRXC TransEnterix
$0.56 /

-0.0184 (-3.18%)

SOL ReneSola
$7.70 /

-0.38 (-4.70%)

ROOT Root
$14.12 /

+0.21 (+1.51%)

LAC Lithium Americas
$9.37 /

-0.145 (-1.52%)

IPOC Social Capital Hedosophia Holdings III
$11.01 /

+0.13 (+1.19%)

HEPA Hepion Pharmaceuticals
$1.90 /

+0.02 (+1.06%)

GP GreenPower Motor
$17.80 /

-0.36 (-1.98%)

FUBO FuboTV
$35.28 /

+5.71 (+19.31%)

GP GreenPower Motor
$17.80 /

-0.36 (-1.98%)

11/25/20 Maxim
GreenPower Motor price target raised to $35 from $22 at Maxim
11/19/20 BTIG
BTIG reiterates Buy rating on GreenPower Motor after investors meetings
11/02/20
Fly Intel: Top five analyst initiations
11/02/20 Maxim
GreenPower Motor initiated with a Buy at Maxim
FUBO FuboTV
$35.28 /

+5.71 (+19.31%)

12/16/20 Wedbush
Wedbush bullish on FuboTV, initiates with an Outperform
12/15/20 Wedbush
FuboTV initiated with an Outperform at Wedbush
12/14/20 BMO Capital
FuboTV price target raised to $33 from $20 at BMO Capital
12/07/20 Oppenheimer
FuboTV price target raised to $30 from $21 at Oppenheimer
TRXC TransEnterix
$0.56 /

-0.0184 (-3.18%)

VLDR Velodyne Lidar
$20.60 /

+0.03 (+0.15%)

12/15/20 Needham
Velodyne Lidar initiated with a Buy at Needham
12/15/20 Needham
Velodyne Lidar initiated with a Buy at Needham
12/10/20
Fly Intel: Top five analyst initiations
12/10/20 Berenberg
Velodyne Lidar initiated with a Buy at Berenberg
VFF Village Farms
$9.93 /

-0.32 (-3.12%)

11/02/20 Raymond James
Village Farms upgraded to Strong Buy from Outperform at Raymond James
09/14/20 Alliance Global Partners
Village Farms price target raised to C$16 from C$14 at Alliance Global Partners
09/08/20 Roth Capital
Roth says deal for PSF solidifies Village Farms as 'leading cannabis supplier'
09/08/20 Raymond James
Village Farms price target raised to $20 from $14 at Raymond James
ROOT Root
$14.12 /

+0.21 (+1.51%)

12/18/20 Credit Suisse
Root initiated with a Neutral at Credit Suisse
11/23/20 Barclays
Root initiated with an Equal Weight at Barclays
11/23/20 Truist
Root initiated with a Buy at Truist
11/23/20 Cantor Fitzgerald
Root initiated with an Overweight at Cantor Fitzgerald
HEPA Hepion Pharmaceuticals
$1.90 /

+0.02 (+1.06%)

12/01/20 Roth Capital
Hepion Pharmaceuticals price target lowered to $8 from $14 at Roth Capital
07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
IPOC Social Capital Hedosophia Holdings III
$11.01 /

+0.13 (+1.19%)

SOL ReneSola
$7.70 /

-0.38 (-4.70%)

12/15/20 Roth Capital
Solar tax credit extension would be positive surprise, says Roth Capital
12/14/20 H.C. Wainwright
ReneSola price target raised to $12 from $4 at H.C. Wainwright
09/17/20 H.C. Wainwright
ReneSola initiated with a Buy at H.C. Wainwright
03/03/20
LD Micro to hold a virtual conference
LAC Lithium Americas
$9.37 /

-0.145 (-1.52%)

10/21/20 Roth Capital
Lithium Americas downgraded to Neutral from Buy at Roth Capital
10/20/20 BMO Capital
Lithium Americas price target raised to C$10 from C$8 at BMO Capital
09/23/20 BMO Capital
BMO thinks Tesla project rights not related to Lithium Americas
06/25/20 BMO Capital
Lithium Americas price target raised to C$5 from C$4.40 at BMO Capital
SOL ReneSola
$7.70 /

-0.38 (-4.70%)

ROOT Root
$14.12 /

+0.21 (+1.51%)

LAC Lithium Americas
$9.37 /

-0.145 (-1.52%)

FUBO FuboTV
$35.28 /

+5.71 (+19.31%)

  • 25
    Nov
  • 28
    Oct
  • 08
    Oct
VLDR Velodyne Lidar
$20.60 /

+0.03 (+0.15%)

ROOT Root
$14.12 /

+0.21 (+1.51%)

GP GreenPower Motor
$17.80 /

-0.36 (-1.98%)

VLDR Velodyne Lidar
$20.60 /

+0.03 (+0.15%)

VFF Village Farms
$9.93 /

-0.32 (-3.12%)

ROOT Root
$14.12 /

+0.21 (+1.51%)

LAC Lithium Americas
$9.37 /

-0.145 (-1.52%)

IPOC Social Capital Hedosophia Holdings III
$11.01 /

+0.13 (+1.19%)

HEPA Hepion Pharmaceuticals
$1.90 /

+0.02 (+1.06%)

FUBO FuboTV
$35.28 /

+5.71 (+19.31%)

VLDR Velodyne Lidar
$20.60 /

+0.03 (+0.15%)

VFF Village Farms
$9.93 /

-0.32 (-3.12%)

SOL ReneSola
$7.70 /

-0.38 (-4.70%)

LAC Lithium Americas
$9.37 /

-0.145 (-1.52%)

IPOC Social Capital Hedosophia Holdings III
$11.01 /

+0.13 (+1.19%)

HEPA Hepion Pharmaceuticals
$1.90 /

+0.02 (+1.06%)

GP GreenPower Motor
$17.80 /

-0.36 (-1.98%)

FUBO FuboTV
$35.28 /

+5.71 (+19.31%)

Hot Stocks
Hepion Pharmaceuticals announces results of study on CRV431 » 07:39
12/02/20
12/02
07:39
12/02/20
07:39
HEPA

Hepion Pharmaceuticals

$1.66 /

-0.01 (-0.60%)

Hepion Pharmaceuticals…

Hepion Pharmaceuticals announced results from a translational research study in which its lead drug candidate, CRV431, decreased formation of a novel class of human blood platelets, called 'procoagulant platelets.' High levels of procoagulant platelets have been associated with transient ischemic attack and stroke.Patients with advanced liver disease often have coagulopathy disorders, diabetes, and dyslipidemia, and may develop hemorrhagic and ischemic diseases including stroke.2 For example, patients with nonalcoholic fatty liver disease and NASH have an increased risk for ischemic stroke, which accounts for 87% of strokes in the United States and is the second leading cause of death globally.3 Additionally, patients with NAFLD may experience more severe stroke which may require more aggressive management of liver disease.4 Nonclinical studies have reported that cyclophilins, the enzymes inhibited by CRV431, contribute to platelet activities, which prompted Hepion to undertake the present in vitro study to examine the effects of CRV431 on platelets.

ShowHide Related Items >><<
HEPA Hepion Pharmaceuticals
$1.66 /

-0.01 (-0.60%)

HEPA Hepion Pharmaceuticals
$1.66 /

-0.01 (-0.60%)

12/01/20 Roth Capital
Hepion Pharmaceuticals price target lowered to $8 from $14 at Roth Capital
07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
  • 25
    Nov
HEPA Hepion Pharmaceuticals
$1.66 /

-0.01 (-0.60%)

HEPA Hepion Pharmaceuticals
$1.66 /

-0.01 (-0.60%)

Recommendations
Hepion Pharmaceuticals price target lowered to $8 from $14 at Roth Capital » 07:52
12/01/20
12/01
07:52
12/01/20
07:52
HEPA

Hepion Pharmaceuticals

$1.66 /

-0.03 (-1.78%)

Roth Capital analyst…

Roth Capital analyst Elemer Piros lowered the firm's price target on Hepion Pharmaceuticals to $8 from $14 and keeps a Buy rating on the shares. The analyst notes that Hepion closed a follow on offering of 23M shares priced at $1.50/share, which caused a significantly higher dilution than he previously anticipated.

ShowHide Related Items >><<
HEPA Hepion Pharmaceuticals
$1.66 /

-0.03 (-1.78%)

HEPA Hepion Pharmaceuticals
$1.66 /

-0.03 (-1.78%)

07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
  • 25
    Nov
HEPA Hepion Pharmaceuticals
$1.66 /

-0.03 (-1.78%)

HEPA Hepion Pharmaceuticals
$1.66 /

-0.03 (-1.78%)

Syndicate
Hepion Pharmaceuticals 20M share Spot Secondary priced at $1.50 » 19:35
11/24/20
11/24
19:35
11/24/20
19:35
HEPA

Hepion Pharmaceuticals

$2.18 /

-0.185 (-7.82%)

The deal priced below the…

The deal priced below the last closing price of $2.18. ThinkEquity is acting as sole book running manager for the offering.

ShowHide Related Items >><<
HEPA Hepion Pharmaceuticals
$2.18 /

-0.185 (-7.82%)

HEPA Hepion Pharmaceuticals
$2.18 /

-0.185 (-7.82%)

07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
HEPA Hepion Pharmaceuticals
$2.18 /

-0.185 (-7.82%)

HEPA Hepion Pharmaceuticals
$2.18 /

-0.185 (-7.82%)

Hot Stocks
Hepion says DSMB approves continuation of Phase 2a Ambition trial » 07:44
11/18/20
11/18
07:44
11/18/20
07:44
HEPA

Hepion Pharmaceuticals

$2.70 /

-0.15 (-5.26%)

Hepion Pharmaceuticals…

Hepion Pharmaceuticals announced that an independent Data Safety Monitoring Board, DSMB,has approved the continuation of the company's Phase 2a 'AMBITION' clinical trial to the next dose level cohort, after evaluating the safety and tolerability of the 75 mg CRV431 dose cohort in NASH patients. The study will now enroll NASH patients in the 225 mg dose cohort.The AMBITION trial is the first placebo-controlled study of CRV431 in NASH patients with evidence of moderate-to-severe fibrosis. In this study, CRV431 is administered orally, once-daily for 28 days. The primary objectives of the trial are to assess safety and tolerability of CRV431, as well as to delineate pharmacokinetics. The secondary outcome measure of the trial is to evaluate decreases in non-invasive antifibrotic markers from baseline to the end of study. The study is being conducted at 10 sites in the U.S.less than/pgreater thanless thanpgreater thanDr. Stephen Harrison MD, Hepion's Consultant Medical Director, commented, "The DSMB review of the first CRV431 dose cohort in the Phase 2a AMBITION trial affirmed there were no safety or tolerability concerns. Moreover, when focusing on parameters of liver chemistry safety labs, reductions in ALT and AST were observed at Day 28. These data are very encouraging for the continued development of CRV431 as an oral, once-daily antifibrotic treatment for NASH patients."We are pleased with the DSMB's positive recommendation and look forward to continuing our AMBITION trial in NASH patients with moderate-to-severe fibrosis," commented Dr. Robert Foster PharmD, PhD, Hepion's CEO. "There are currently no approved treatments for NASH, which affects approximately 17 million people in the U.S. and may lead to cirrhosis, cancer, and death.

ShowHide Related Items >><<
HEPA Hepion Pharmaceuticals
$2.70 /

-0.15 (-5.26%)

HEPA Hepion Pharmaceuticals
$2.70 /

-0.15 (-5.26%)

07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
HEPA Hepion Pharmaceuticals
$2.70 /

-0.15 (-5.26%)

HEPA Hepion Pharmaceuticals
$2.70 /

-0.15 (-5.26%)

Conference/Events
Roth Capital to hold a webinar » 08:30
10/28/20
10/28
08:30
10/28/20
08:30
ACER

Acer Therapeutics

$2.64 /

-0.08 (-2.94%)

, APLS

Apellis

$35.59 /

-0.33 (-0.92%)

, ARDS

Aridis Pharmaceuticals

$6.85 /

-0.19 (-2.70%)

, CRVS

Corvus Pharmaceuticals

$4.07 /

+0.2 (+5.17%)

, CWBR

CohBar

$0.92 /

+0.0169 (+1.87%)

, DRRX

Durect

$1.80 /

-0.065 (-3.49%)

, HEPA

Hepion Pharmaceuticals

$3.39 /

-0.01 (-0.29%)

, HGEN

Humanigen

$10.83 /

-1.17 (-9.75%)

, IMUX

Immunic

$17.52 /

+0.82 (+4.91%)

, LIFE

aTyr Pharma

$3.22 /

-0.025 (-0.77%)

, RDHL

RedHill Biopharma

$9.75 /

-0.11 (-1.12%)

, TFFP

TFF Pharmaceuticals

$14.24 /

+0.01 (+0.07%)

, XAIR

Beyond Air

$5.42 /

-0.18 (-3.21%)

COVID-19 Therapeutics in…

COVID-19 Therapeutics in Development will be held on October 28 at 9 am. Webcast Link

ShowHide Related Items >><<
XAIR Beyond Air
$5.42 /

-0.18 (-3.21%)

TFFP TFF Pharmaceuticals
$14.24 /

+0.01 (+0.07%)

RDHL RedHill Biopharma
$9.75 /

-0.11 (-1.12%)

LIFE aTyr Pharma
$3.22 /

-0.025 (-0.77%)

IMUX Immunic
$17.52 /

+0.82 (+4.91%)

HGEN Humanigen
$10.83 /

-1.17 (-9.75%)

HEPA Hepion Pharmaceuticals
$3.39 /

-0.01 (-0.29%)

DRRX Durect
$1.80 /

-0.065 (-3.49%)

CWBR CohBar
$0.92 /

+0.0169 (+1.87%)

CRVS Corvus Pharmaceuticals
$4.07 /

+0.2 (+5.17%)

ARDS Aridis Pharmaceuticals
$6.85 /

-0.19 (-2.70%)

APLS Apellis
$35.59 /

-0.33 (-0.92%)

ACER Acer Therapeutics
$2.64 /

-0.08 (-2.94%)

ACER Acer Therapeutics
$2.64 /

-0.08 (-2.94%)

APLS Apellis
$35.59 /

-0.33 (-0.92%)

09/01/20
Fly Intel: Top five analyst initiations
08/31/20 Stifel
Apellis initiated with a Buy at Stifel
07/20/20 Roth Capital
Apellis initiated with a Buy at Roth Capital
06/16/20 BTIG
Apellis initiated with a Neutral at BTIG
ARDS Aridis Pharmaceuticals
$6.85 /

-0.19 (-2.70%)

05/15/20 H.C. Wainwright
Aridis Pharmaceuticals price target raised to $11 from $7 at H.C. Wainwright
02/19/20 Roth Capital
Aridis Pharmaceuticals initiated with a Buy at Roth Capital
01/27/20 Cantor Fitzgerald
Cantor sees 'meaningful' coronavirus opportunity for Aridis Pharmaceuticals
12/30/19
Fly Intel: Top five analyst actions
CRVS Corvus Pharmaceuticals
$4.07 /

+0.2 (+5.17%)

10/05/20 Wedbush
Corvus' COVID-19 program data supports further advancement, says Wedbush
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
03/10/20 H.C. Wainwright
Corvus Pharmaceuticals initiated with a Buy at H.C. Wainwright
12/09/19 Mizuho
Corvus pipeline updates 'can only be additive,' says Mizuho
CWBR CohBar
$0.92 /

+0.0169 (+1.87%)

10/15/20 WBB Securities
CohBar initiated with a Speculative Buy at WBB Securities
10/15/20 WBB Securities
CohBar initiated with a Buy at WBB Securities
09/17/20 Roth Capital
CohBar initiated with a Buy at Roth Capital
05/27/20 Brookline
CohBar initiated with a Buy at Brookline
DRRX Durect
$1.80 /

-0.065 (-3.49%)

10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
10/12/20 Roth Capital
Durect initiated with a Buy at Roth Capital
09/24/20 H.C. Wainwright
Durect study designed to support full approval, says H.C. Wainwright
07/30/20 Oppenheimer
Durect initiated with an Outperform at Oppenheimer
HEPA Hepion Pharmaceuticals
$3.39 /

-0.01 (-0.29%)

07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
HGEN Humanigen
$10.83 /

-1.17 (-9.75%)

10/21/20
Fly Intel: Top five analyst initiations
10/21/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
10/20/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
10/14/20 H.C. Wainwright
Humanigen initiated with a Buy at H.C. Wainwright
IMUX Immunic
$17.52 /

+0.82 (+4.91%)

10/02/20 SVB Leerink
Immunic initiated with an Outperform at SVB Leerink
10/02/20 SVB Leerink
Immunic initiated with an Outperform at SVB Leerink
09/28/20 Roth Capital
Roth Capital encouraged by Immunic update on COVID-19 candidate
09/28/20 Piper Sandler
Immunic news removes safety concerns for IMU-838, says Piper Sandler
LIFE aTyr Pharma
$3.22 /

-0.025 (-0.77%)

08/17/20 H.C. Wainwright
aTyr Pharma upgraded to Buy from Neutral at H.C. Wainwright
06/18/20 Roth Capital
aTyr Pharma should be bought on ATYR-1923 update, says Roth Capital
04/30/20 Roth Capital
aTyr Pharma '1923 another 'shot on goal' in COVID-19 fight, says Roth Capital
03/27/20 H.C. Wainwright
aTyr Pharma downgraded to Neutral from Buy at H.C. Wainwright
RDHL RedHill Biopharma
$9.75 /

-0.11 (-1.12%)

09/11/20 BTIG
RedHill Biopharma initiated with a Buy at BTIG
08/14/20 Roth Capital
Roth Capital maintains Buy on RedHill after 'noisy' quarter
07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
TFFP TFF Pharmaceuticals
$14.24 /

+0.01 (+0.07%)

10/15/20 Roth Capital
TFF Pharmaceuticals price target raised to $23 from $18 at Roth Capital
08/17/20 Maxim
TFF Pharmaceuticals price target raised to $18 from $12 at Maxim
08/14/20 Roth Capital
TFF Pharmaceuticals price target raised to $18 from $15 at Roth Capital
07/08/20 Maxim
TFF Pharmaceuticals initiated with a Buy at Maxim
XAIR Beyond Air
$5.42 /

-0.18 (-3.21%)

XAIR Beyond Air
$5.42 /

-0.18 (-3.21%)

TFFP TFF Pharmaceuticals
$14.24 /

+0.01 (+0.07%)

RDHL RedHill Biopharma
$9.75 /

-0.11 (-1.12%)

LIFE aTyr Pharma
$3.22 /

-0.025 (-0.77%)

IMUX Immunic
$17.52 /

+0.82 (+4.91%)

DRRX Durect
$1.80 /

-0.065 (-3.49%)

CRVS Corvus Pharmaceuticals
$4.07 /

+0.2 (+5.17%)

ARDS Aridis Pharmaceuticals
$6.85 /

-0.19 (-2.70%)

APLS Apellis
$35.59 /

-0.33 (-0.92%)

ACER Acer Therapeutics
$2.64 /

-0.08 (-2.94%)

  • 18
    Sep
  • 05
    Aug
  • 10
    Jun
  • 06
    Feb
  • 09
    Jan
  • 10
    Dec
XAIR Beyond Air
$5.42 /

-0.18 (-3.21%)

TFFP TFF Pharmaceuticals
$14.24 /

+0.01 (+0.07%)

RDHL RedHill Biopharma
$9.75 /

-0.11 (-1.12%)

IMUX Immunic
$17.52 /

+0.82 (+4.91%)

HEPA Hepion Pharmaceuticals
$3.39 /

-0.01 (-0.29%)

DRRX Durect
$1.80 /

-0.065 (-3.49%)

CRVS Corvus Pharmaceuticals
$4.07 /

+0.2 (+5.17%)

ACER Acer Therapeutics
$2.64 /

-0.08 (-2.94%)

XAIR Beyond Air
$5.42 /

-0.18 (-3.21%)

TFFP TFF Pharmaceuticals
$14.24 /

+0.01 (+0.07%)

HGEN Humanigen
$10.83 /

-1.17 (-9.75%)

HEPA Hepion Pharmaceuticals
$3.39 /

-0.01 (-0.29%)

DRRX Durect
$1.80 /

-0.065 (-3.49%)

ACER Acer Therapeutics
$2.64 /

-0.08 (-2.94%)

Over a quarter ago
Hot Stocks
Hepion Pharmaceuticals reports 'positive activity' of CRV431 against SARS-CoV-2 » 08:19
09/17/20
09/17
08:19
09/17/20
08:19
HEPA

Hepion Pharmaceuticals

$3.40 /

+0.14 (+4.29%)

Hepion Pharmaceuticals…

Hepion Pharmaceuticals said in a release, "Hepion Pharmaceuticals announced that a study of Hepion's CRV431 conducted by the National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health, or NIH, demonstrated positive antiviral activity against SARS coronavirus-2 (SARS-CoV-2). Under NIAID's suite of preclinical services, or PCS, and with NIAID funding, Hepion was able to study the impact of CRV431 on SARS-CoV-2. This in vitro study tested CRV431 at concentrations of 0.0032 to 10 microM and a positive control compound, a protease inhibitor, at 0.032 to 100 microgram/ml in Caco-2 cells infected with SARS-CoV-2. CRV431 treatment was found to inhibit production of infectious virus in these cells with almost five-times greater potency than the positive control compound in this study. The concentration of CRV431 required to inhibit virus production by 90% (IC90) was 1.5 microM versus 7.3 microM for the positive control compound. Separate experiments that evaluated cellular toxicities independent of virus infection showed no significant CRV431 cellular toxicity, indicating that CRV431 antiviral activity was due to specific effects on the virus."

ShowHide Related Items >><<
HEPA Hepion Pharmaceuticals
$3.40 /

+0.14 (+4.29%)

HEPA Hepion Pharmaceuticals
$3.40 /

+0.14 (+4.29%)

07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
HEPA Hepion Pharmaceuticals
$3.40 /

+0.14 (+4.29%)

HEPA Hepion Pharmaceuticals
$3.40 /

+0.14 (+4.29%)

Hot Stocks
Hepion Pharmaceuticals completes final dosing in Phase 1b MAD study of CRV431 » 07:35
09/01/20
09/01
07:35
09/01/20
07:35
HEPA

Hepion Pharmaceuticals

$3.33 /

+0.12 (+3.74%)

Hepion Pharmaceuticals…

Hepion Pharmaceuticals said in a release, "Hepion Pharmaceuticals announced that CRV431 dosing has now been completed in all subjects enrolled in the Phase 1b multiple ascending dose, or MAD, study of CRV431. The open-label MAD study was designed to assess safety, tolerability and pharmacokinetics of CRV431, administered orally to healthy volunteers, once daily for 28 days. The study examined doses of 75 mg, 150 mg, 225 mg, 300 mg and 375 mg."

ShowHide Related Items >><<
HEPA Hepion Pharmaceuticals
$3.33 /

+0.12 (+3.74%)

HEPA Hepion Pharmaceuticals
$3.33 /

+0.12 (+3.74%)

07/20/20 Roth Capital
Hepion Pharmaceuticals transferred with a Buy rating at Roth Capital
03/20/20 Roth Capital
Roth Capital says Hepion's CRV431 could be used in COVID-19 treatment
11/22/19 Brookline
Hepion Pharmaceuticals initiated with a Buy at Brookline
11/07/19
Fly Intel: Top analyst initiations
HEPA Hepion Pharmaceuticals
$3.33 /

+0.12 (+3.74%)

HEPA Hepion Pharmaceuticals
$3.33 /

+0.12 (+3.74%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.